首页 > 最新文献

Drug, Healthcare and Patient Safety最新文献

英文 中文
Prevalence and Factors Associated with Dyslipidemia Among People Living with HIV/AIDS on Follow-Up Care at a Tertiary Care Hospital in Ethiopia: A Cross-Sectional Study. 埃塞俄比亚一家三级医院随访的艾滋病毒/艾滋病感染者中血脂异常的患病率及其相关因素:一项横断面研究。
IF 2.2 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-05-19 eCollection Date: 2023-01-01 DOI: 10.2147/DHPS.S395037
Alemayehu Assefa, Alfoalem Araba Abiye, Tamrat Assefa Tadesse, Minyahil Woldu

Background: Despite its importance as a major risk factor for cardiovascular disease, dyslipidemia remains poorly characterized in the African population.

Objective: To assess the prevalence and factors associated with dyslipidemia in people with HIV/AIDS in follow-up at Zewditu Memorial Hospital, Addis Ababa, Ethiopia.

Materials and methods: A hospital-based retrospective cross-sectional study evaluated the charts of 288 people living with HIV/AIDS who had received Highly Active Antiretroviral Treatment for at least six months at Zewditu Memorial Hospital from July to September 2021. Sociodemographic and clinical data were collected from the patient's charts. Statistical analysis was performed using the Statistical Package for Social Sciences software version 25.

Results: The overall prevalence of dyslipidemia was 55.2% in people living with HIV/AIDS. The prevalence of high-density lipoprotein cholesterol <40 mg/dl in men and <50 in women was 46.9%; total cholesterol ≥200 mg/dl was 22.6%; triglycerides ≥150 mg/dl was 18.8%, and low-density lipoprotein ≥130 mg/dl was 4.9%. Sex [Female adjusted odds ratio (AOR) = 0.595, 95% CI: 0.37-0.956], age greater than 40 years (AOR = 1.026, 95% CI: 1.005-1.048), body mass index >25 kg/m2 (AOR = 1.767, 95% CI: 1.099-2.84), viral load >50 (AOR = 0.477, 95% CI: 0.27-0.842), and CD4 <500 (AOR = 1.938, 95% CI: 1.18-3.183) were identified as determinants of dyslipidemia.

Conclusion: There was a high prevalence of dyslipidemia among study participants compared to several studies published in a similar population. Being male, older age, higher BMI, low CD4 count, and viral load of < 50 copies/mL were associated with dyslipidemia in people living with HIV/AIDS. Therefore, lipid profile measurements at baseline must be part of routine care to prevent the devastating effects of dyslipidemia.

背景:尽管血脂异常是心血管疾病的主要风险因素,但在非洲人口中,血脂异常的特点仍然不甚明了:尽管血脂异常是心血管疾病的一个主要风险因素,但在非洲人群中,血脂异常的特点仍然不明显:评估埃塞俄比亚亚的斯亚贝巴 Zewditu 纪念医院随访的艾滋病毒/艾滋病患者中血脂异常的患病率和相关因素:这项以医院为基础的回顾性横断面研究评估了 2021 年 7 月至 9 月期间在 Zewditu 纪念医院接受至少 6 个月高活性抗逆转录病毒治疗的 288 名艾滋病毒/艾滋病感染者的病历。研究人员从患者病历中收集了社会人口学和临床数据。统计分析采用社会科学统计软件包第 25 版:结果:在艾滋病毒/艾滋病感染者中,血脂异常的总患病率为 55.2%。高密度脂蛋白胆固醇为 25 kg/m2(AOR = 1.767,95% CI:1.099-2.84)、病毒载量大于 50(AOR = 0.477,95% CI:0.27-0.842)、CD4 结语:血脂异常在艾滋病毒/艾滋病患者中的发病率很高:与在类似人群中发表的几项研究相比,研究参与者中血脂异常的发生率较高。男性、年龄较大、体重指数较高、CD4计数较低以及病毒载量小于50拷贝/毫升与艾滋病毒/艾滋病感染者的血脂异常有关。因此,必须将基线血脂测量作为常规护理的一部分,以防止血脂异常的破坏性影响。
{"title":"Prevalence and Factors Associated with Dyslipidemia Among People Living with HIV/AIDS on Follow-Up Care at a Tertiary Care Hospital in Ethiopia: A Cross-Sectional Study.","authors":"Alemayehu Assefa, Alfoalem Araba Abiye, Tamrat Assefa Tadesse, Minyahil Woldu","doi":"10.2147/DHPS.S395037","DOIUrl":"10.2147/DHPS.S395037","url":null,"abstract":"<p><strong>Background: </strong>Despite its importance as a major risk factor for cardiovascular disease, dyslipidemia remains poorly characterized in the African population.</p><p><strong>Objective: </strong>To assess the prevalence and factors associated with dyslipidemia in people with HIV/AIDS in follow-up at Zewditu Memorial Hospital, Addis Ababa, Ethiopia.</p><p><strong>Materials and methods: </strong>A hospital-based retrospective cross-sectional study evaluated the charts of 288 people living with HIV/AIDS who had received Highly Active Antiretroviral Treatment for at least six months at Zewditu Memorial Hospital from July to September 2021. Sociodemographic and clinical data were collected from the patient's charts. Statistical analysis was performed using the Statistical Package for Social Sciences software version 25.</p><p><strong>Results: </strong>The overall prevalence of dyslipidemia was 55.2% in people living with HIV/AIDS. The prevalence of high-density lipoprotein cholesterol <40 mg/dl in men and <50 in women was 46.9%; total cholesterol ≥200 mg/dl was 22.6%; triglycerides ≥150 mg/dl was 18.8%, and low-density lipoprotein ≥130 mg/dl was 4.9%. Sex [Female adjusted odds ratio (AOR) = 0.595, 95% CI: 0.37-0.956], age greater than 40 years (AOR = 1.026, 95% CI: 1.005-1.048), body mass index >25 kg/m<sup>2</sup> (AOR = 1.767, 95% CI: 1.099-2.84), viral load >50 (AOR = 0.477, 95% CI: 0.27-0.842), and CD4 <500 (AOR = 1.938, 95% CI: 1.18-3.183) were identified as determinants of dyslipidemia.</p><p><strong>Conclusion: </strong>There was a high prevalence of dyslipidemia among study participants compared to several studies published in a similar population. Being male, older age, higher BMI, low CD4 count, and viral load of < 50 copies/mL were associated with dyslipidemia in people living with HIV/AIDS. Therefore, lipid profile measurements at baseline must be part of routine care to prevent the devastating effects of dyslipidemia.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/81/e9/dhps-15-93.PMC10397381.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9954876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Delta-8,一种大麻衍生的四氢大麻酚异构体:评估食品药品管理局不良事件报告系统 (FAERS) 数据库中的病例报告数据。
IF 2.2 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-29 eCollection Date: 2023-01-01 DOI: 10.2147/DHPS.S391857
Teresa A Simon, John H Simon, Erin G Heaning, Andres Gomez-Caminero, Jahan P Marcu

Purpose: The aim of this study was to characterize the frequency of adverse effects where delta-8 tetrahydrocannabinol (D8-THC) was identified as a possible suspect drug in the FDA Adverse Event Reporting System (FAERS) database.

Methods: A case-series design was used.

Results: A total of 183 cases listed D8-THC as a suspect drug in FAERS as of June 30, 2021. The most common events included dyspnea, respiratory disorder, and seizure. The reporting odds ratios were consistently and significantly greater than 2, a 2-fold increase from 2019 to 2021, indicating a potential safety signal.

Conclusion: The first report of D8-THC, in the FAERS database, as a suspect drug appears to be in 2011. Overall, there are 183 total cases listing D8-THC as a suspect drug in the FAERS database as of June 30, 2021. Of the 183 cases, most were respiratory in nature.

目的:本研究旨在描述在美国食品药物管理局不良事件报告系统(FAERS)数据库中,δ-8四氢大麻酚(D8-THC)被确定为可能的可疑药物的不良反应频率:方法:采用病例序列设计:结果:截至2021年6月30日,共有183个病例在FAERS中将D8-THC列为可疑药物。最常见的事件包括呼吸困难、呼吸紊乱和癫痫发作。报告的几率比持续显著大于 2,从 2019 年到 2021 年增加了 2 倍,表明存在潜在的安全信号:结论:FAERS数据库中首次将D8-THC列为可疑药物的报告似乎是在2011年。截至 2021 年 6 月 30 日,FAERS 数据库中将 D8-THC 列为可疑药物的病例共有 183 例。在这 183 个案例中,大多数属于呼吸系统疾病。
{"title":"Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.","authors":"Teresa A Simon, John H Simon, Erin G Heaning, Andres Gomez-Caminero, Jahan P Marcu","doi":"10.2147/DHPS.S391857","DOIUrl":"10.2147/DHPS.S391857","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to characterize the frequency of adverse effects where delta-8 tetrahydrocannabinol (D8-THC) was identified as a possible suspect drug in the FDA Adverse Event Reporting System (FAERS) database.</p><p><strong>Methods: </strong>A case-series design was used.</p><p><strong>Results: </strong>A total of 183 cases listed D8-THC as a suspect drug in FAERS as of June 30, 2021. The most common events included dyspnea, respiratory disorder, and seizure. The reporting odds ratios were consistently and significantly greater than 2, a 2-fold increase from 2019 to 2021, indicating a potential safety signal.</p><p><strong>Conclusion: </strong>The first report of D8-THC, in the FAERS database, as a suspect drug appears to be in 2011. Overall, there are 183 total cases listing D8-THC as a suspect drug in the FAERS database as of June 30, 2021. Of the 183 cases, most were respiratory in nature.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/95/9f/dhps-15-25.PMC9894081.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10659633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Clinical Efficacy, Safety, and Tolerability of Vancomycin for the Treatment of Recurrent Clostridioides difficile Infection - A Systematic Review. 万古霉素治疗复发性艰难梭菌感染的临床疗效、安全性和耐受性——系统综述。
IF 1.6 Q3 Medicine Pub Date : 2023-01-01 DOI: 10.2147/DHPS.S348501
Maja Johanne Søndergaard Knudsen, Ingrid Maria Cecilia Rubin, Andreas Munk Petersen
Introduction The aim of this systematic review of randomized clinical trials (RCTs) was to examine the efficacy, safety, and tolerability of vancomycin for treatment of recurrent Clostridioides difficile infection (rCDI). Methods The PubMed database was searched from inception to August 23, 2022. An initial screening was performed followed by a full-text evaluation of the papers. Inclusion criteria were RCTs investigating vancomycin for treatment of rCDI. Results A total of six studies and 269 patients were included in the review. Three studies used a fixed dose regimen of vancomycin, one study used pulse regimen, one study used a taper-and-pulse regimen, and one study used a taper-and-pulse regimen for the participants with two or more recurrences. The resolution of infection varied from 19% to 58.3% in five of six studies reporting this as an outcome. Four out of six studies reported new episodes of rCDI as an intervention outcome, in those studies 50–63% of participants experienced rCDI. Regarding the safety and tolerability of vancomycin treatment for rCDI, one study described several adverse events regarding gastrointestinal discomfort along with fatigue and skin rash. There were no records of serious adverse events in the included studies. Conclusion While oral vancomycin is mostly safe and well tolerated in the RCTs reviewed here, the efficacy for treating rCDI varies greatly from 19–58.3%, and 50–63% of participants experienced new episodes of rCDI.
简介:本系统综述随机临床试验(RCTs)的目的是研究万古霉素治疗复发性艰难梭菌感染(rCDI)的有效性、安全性和耐受性。方法:检索PubMed数据库自成立至2022年8月23日。首先进行初步筛选,然后对论文进行全文评估。纳入标准为研究万古霉素治疗rCDI的随机对照试验。结果:共纳入6项研究和269例患者。三项研究使用固定剂量万古霉素治疗方案,一项研究使用脉冲治疗方案,一项研究使用锥形脉冲治疗方案,一项研究使用锥形脉冲治疗方案,一项研究对两次或两次以上复发的参与者使用锥形脉冲治疗方案。在报道这一结果的6项研究中,有5项研究的感染率从19%到58.3%不等。6项研究中有4项报告了rCDI的新发作作为干预结果,在这些研究中,50-63%的参与者经历了rCDI。关于万古霉素治疗rCDI的安全性和耐受性,一项研究描述了胃肠道不适、疲劳和皮疹等不良事件。在纳入的研究中没有严重不良事件的记录。结论:虽然在本文回顾的随机对照试验中,口服万古霉素大多是安全且耐受性良好的,但治疗rCDI的疗效差异很大,在19-58.3%之间,50-63%的参与者出现了新的rCDI发作。
{"title":"The Clinical Efficacy, Safety, and Tolerability of Vancomycin for the Treatment of Recurrent <i>Clostridioides difficile</i> Infection - A Systematic Review.","authors":"Maja Johanne Søndergaard Knudsen,&nbsp;Ingrid Maria Cecilia Rubin,&nbsp;Andreas Munk Petersen","doi":"10.2147/DHPS.S348501","DOIUrl":"https://doi.org/10.2147/DHPS.S348501","url":null,"abstract":"Introduction The aim of this systematic review of randomized clinical trials (RCTs) was to examine the efficacy, safety, and tolerability of vancomycin for treatment of recurrent Clostridioides difficile infection (rCDI). Methods The PubMed database was searched from inception to August 23, 2022. An initial screening was performed followed by a full-text evaluation of the papers. Inclusion criteria were RCTs investigating vancomycin for treatment of rCDI. Results A total of six studies and 269 patients were included in the review. Three studies used a fixed dose regimen of vancomycin, one study used pulse regimen, one study used a taper-and-pulse regimen, and one study used a taper-and-pulse regimen for the participants with two or more recurrences. The resolution of infection varied from 19% to 58.3% in five of six studies reporting this as an outcome. Four out of six studies reported new episodes of rCDI as an intervention outcome, in those studies 50–63% of participants experienced rCDI. Regarding the safety and tolerability of vancomycin treatment for rCDI, one study described several adverse events regarding gastrointestinal discomfort along with fatigue and skin rash. There were no records of serious adverse events in the included studies. Conclusion While oral vancomycin is mostly safe and well tolerated in the RCTs reviewed here, the efficacy for treating rCDI varies greatly from 19–58.3%, and 50–63% of participants experienced new episodes of rCDI.","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6b/8e/dhps-15-63.PMC10039659.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9567921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Validation of the Safety Attitudes Questionnaire for Assessing Patient Safety Culture in Critical Care Settings of Three Selected Ugandan Hospitals. 评估乌干达三家选定医院重症监护环境中患者安全文化的安全态度问卷的有效性。
IF 1.6 Q3 Medicine Pub Date : 2023-01-01 DOI: 10.2147/DHPS.S389978
Joseph Atukwatse, Vallence Niyonzima, Cliff Asher Aliga, Jalia Nakandi Serwadda, Rosemary Nankunda, Catherine Nakiganda, Peninah Komugabe, Hanifah Nantongo

Background: The safety attitudes questionnaire (SAQ) short form (2006) is important for assessing patient safety culture in clinical environments. However, little is known about its validity and applicability in Uganda. This study validated the SAQ short form (2006) for use in assessing patient safety culture in critical care settings of hospitals in the Ugandan context.

Methods: Using a sequential exploratory mixed-methods research design, the face, content and construct validity for the SAQ short form (2006) was assessed in a multi-phased approach. A panel of eight (8) purposively selected experts assessed the face and content validity in rounds 1 and 2, respectively, while construct validity was assessed in round 3 using data from a cross-sectional survey of 256 frontline health workers in critical care settings of the selected hospitals. Analysis of survey data followed confirmatory factor analysis. Cronbach's alpha examined internal reliability.

Results: Of the 36 items in the tool's original version, 33 were rated clear, with a score of 100% on face validity. The use of contextual vocabulary and formatting issues arose as concerns. The S-CVI/Ave was 100%, and S-CVI/UA was 86.1%. Four new items added on effective communication as another dimension of patient safety culture. The survey had KMO=0.8605, the a priori-based model had a scale Cronbach's alpha=0.8881, with unsatisfactory goodness of fit (RMSEA=0.051, 90% CI: 0.044-0.057, pclose=0.427; chi-square=694.28, p <0.001; CFI=0.884, TLI=0.871). The modified final model had a scale Cronbach's alpha =0.8967 and satisfactory goodness of fit (RMSEA=0.030, 90% CI: 0.019-0.039, pclose=1.000; chi-square=424.98, p=0.002; CFI=0.966, TLI=0.960).

Conclusion: In the tool's original form, the face validity was lacking despite satisfactory scores on item clarity. Content validity was adequate, while construct validity required modifications in construct specifications. Reliability was adequate before and after specification modifications. The modified version has adequate psychometric properties for Uganda.

背景:安全态度问卷(SAQ)简短形式(2006)对评估临床环境中的患者安全文化很重要。然而,人们对它在乌干达的有效性和适用性知之甚少。本研究验证了SAQ简表(2006年)用于评估乌干达医院重症监护环境中的患者安全文化。方法:采用顺序探索性混合方法研究设计,采用多阶段方法对SAQ短表(2006)的面、内容和结构效度进行评估。有目的选择的8位专家小组分别在第1轮和第2轮评估了面孔效度和内容效度,而在第3轮评估了结构效度,使用的数据来自选定医院重症监护环境中256名一线卫生工作者的横断面调查。对调查数据进行验证性因子分析。Cronbach's alpha检验内部信度。结果:在原始版本的36个项目中,33个项目被评为清晰,面部效度得分为100%。上下文词汇的使用和格式问题引起了人们的关注。S-CVI/Ave为100%,S-CVI/UA为86.1%。增加了四个关于有效沟通的新项目,作为患者安全文化的另一个维度。调查的KMO=0.8605,基于优先级的模型的量表Cronbach's alpha=0.8881,拟合优度不理想(RMSEA=0.051, 90% CI: 0.044-0.057, pclose=0.427;卡方=694.28,pclose=1.000;χ2 = 424.98,p = 0.002;CFI = 0.966, = 0.960 TLI)。结论:在工具的原始形式中,尽管项目清晰度得分令人满意,但缺乏面部效度。内容效度是足够的,而构造效度需要对构造规范进行修改。在规格修改之前和之后,可靠性都是足够的。修改后的版本对乌干达有足够的心理测量特性。
{"title":"Validation of the Safety Attitudes Questionnaire for Assessing Patient Safety Culture in Critical Care Settings of Three Selected Ugandan Hospitals.","authors":"Joseph Atukwatse,&nbsp;Vallence Niyonzima,&nbsp;Cliff Asher Aliga,&nbsp;Jalia Nakandi Serwadda,&nbsp;Rosemary Nankunda,&nbsp;Catherine Nakiganda,&nbsp;Peninah Komugabe,&nbsp;Hanifah Nantongo","doi":"10.2147/DHPS.S389978","DOIUrl":"https://doi.org/10.2147/DHPS.S389978","url":null,"abstract":"<p><strong>Background: </strong>The safety attitudes questionnaire (SAQ) short form (2006) is important for assessing patient safety culture in clinical environments. However, little is known about its validity and applicability in Uganda. This study validated the SAQ short form (2006) for use in assessing patient safety culture in critical care settings of hospitals in the Ugandan context.</p><p><strong>Methods: </strong>Using a sequential exploratory mixed-methods research design, the face, content and construct validity for the SAQ short form (2006) was assessed in a multi-phased approach. A panel of eight (8) purposively selected experts assessed the face and content validity in rounds 1 and 2, respectively, while construct validity was assessed in round 3 using data from a cross-sectional survey of 256 frontline health workers in critical care settings of the selected hospitals. Analysis of survey data followed confirmatory factor analysis. Cronbach's alpha examined internal reliability.</p><p><strong>Results: </strong>Of the 36 items in the tool's original version, 33 were rated clear, with a score of 100% on face validity. The use of contextual vocabulary and formatting issues arose as concerns. The S-CVI/<sub>Ave</sub> was 100%, and S-CVI/<sub>UA</sub> was 86.1%. Four new items added on effective communication as another dimension of patient safety culture. The survey had KMO=0.8605, the a priori-based model had a scale Cronbach's alpha=0.8881, with unsatisfactory goodness of fit (RMSEA=0.051, 90% CI: 0.044-0.057, <i>p</i>close=0.427; chi-square=694.28, <i>p</i> <0.001; CFI=0.884, TLI=0.871). The modified final model had a scale Cronbach's alpha =0.8967 and satisfactory goodness of fit (RMSEA=0.030, 90% CI: 0.019-0.039, <i>p</i>close=1.000; chi-square=424.98, <i>p</i>=0.002; CFI=0.966, TLI=0.960).</p><p><strong>Conclusion: </strong>In the tool's original form, the face validity was lacking despite satisfactory scores on item clarity. Content validity was adequate, while construct validity required modifications in construct specifications. Reliability was adequate before and after specification modifications. The modified version has adequate psychometric properties for Uganda.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a7/dc/dhps-15-13.PMC9885870.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10642161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Self-Medication and Associated Factors Among Pregnant Women in Rural Ethiopia: The Importance of Husband Education in Ensuring a Safe Pregnancy. 埃塞俄比亚农村孕妇的自我药疗和相关因素:丈夫教育在确保安全怀孕中的重要性。
IF 1.6 Q3 Medicine Pub Date : 2023-01-01 DOI: 10.2147/DHPS.S394346
Takele Deribu Tujuba, Desalegn Chilo, Endegena Abebe, Sabit Zenu

Background: Self-medication is the use of drugs without a medical prescription to treat self-identified illnesses; it is also the continued use of drugs without a physician's order for recurring symptoms, either by sharing or purchasing them from unlicensed vendors. It entails substantial risk to pregnant women and fetuses. Magnitude of the problem and its factors among rural pregnant women is not studied in Ethiopia.

Objective: This study aimed to assess the prevalence of self-medication practice and identify its associated factors among pregnant women in rural Southwest Shewa, Ethiopia.

Methods: A cross-sectional study was conducted on 585 randomly selected pregnant women in selected rural public health institutions from May to July 2021. Data was collected by using an interviewer-administered pretested structured questionnaire. Multivariable logistic regression was used to identify factors associated with self-medication. Variables with p-value <0.05 for the 95% confidence interval of the adjusted odds ratio were considered statistically significant.

Results: A total of 585 pregnant women participated in the study with a response rate of 92.3%. The prevalence of self-medication among pregnant women was 19.8%. Primigravidity (AOR = 2.7, 95% CI: 1.2-6.1), lower educational status of husbands (AOR = 3.6, 95% CI: 1.02-12.9), living close to health facilities (AOR = 0.23, 95% CI: 0.09-0.6) and knowing one's own gestational age (AOR = 0.5,95% CI: 0.30-0.9) were significantly associated with self-medication practice.

Conclusion and recommendation: One in five of the pregnant women practiced self-medication during the current pregnancy. Primigravidity and lower educational status of husbands were associated with a higher probability of self-medication. Knowing gestational age and living close to health facilities were associated with a lower likelihood of practicing self-medication. Rational drug use has to be promoted among pregnant women. Maternal and child health interventions should also target husbands. Health education has to be strengthened to help pregnant women have a safe pregnancy.

背景:自我药疗是指在没有医疗处方的情况下使用药物治疗自我认定的疾病;它还包括在没有医生处方的情况下,因反复出现的症状而继续使用药物,要么与他人合用,要么从无证商贩处购买。它会给孕妇和胎儿带来巨大的风险。埃塞俄比亚没有研究农村孕妇中这一问题的严重程度及其因素。目的:本研究旨在评估自我药疗实践的流行率,并确定其相关因素在农村西南谢瓦,埃塞俄比亚孕妇。方法:采用横断面研究方法,随机抽取2021年5 - 7月在选定农村公共卫生机构就诊的孕妇585名。数据收集采用访谈者管理的预测试结构化问卷。采用多变量logistic回归来确定与自我用药相关的因素。p值变量结果:共有585名孕妇参与研究,有效率为92.3%。孕妇自我药疗率为19.8%。原始迁移(AOR = 2.7, 95% CI: 1.2-6.1)、丈夫受教育程度较低(AOR = 3.6, 95% CI: 1.02-12.9)、居住在卫生设施附近(AOR = 0.23, 95% CI: 0.09-0.6)和知道自己的胎龄(AOR = 0.5,95% CI: 0.30-0.9)与自我用药实践显著相关。结论和建议:五分之一的孕妇在怀孕期间进行了自我药疗。原发性和较低教育程度的丈夫与较高的自我药疗可能性相关。了解胎龄和住在卫生机构附近与较低的自我药疗可能性有关。应在孕妇中提倡合理用药。妇幼保健干预措施也应针对丈夫。加强健康教育,帮助孕妇安全怀孕。
{"title":"Self-Medication and Associated Factors Among Pregnant Women in Rural Ethiopia: The Importance of Husband Education in Ensuring a Safe Pregnancy.","authors":"Takele Deribu Tujuba,&nbsp;Desalegn Chilo,&nbsp;Endegena Abebe,&nbsp;Sabit Zenu","doi":"10.2147/DHPS.S394346","DOIUrl":"https://doi.org/10.2147/DHPS.S394346","url":null,"abstract":"<p><strong>Background: </strong>Self-medication is the use of drugs without a medical prescription to treat self-identified illnesses; it is also the continued use of drugs without a physician's order for recurring symptoms, either by sharing or purchasing them from unlicensed vendors. It entails substantial risk to pregnant women and fetuses. Magnitude of the problem and its factors among rural pregnant women is not studied in Ethiopia.</p><p><strong>Objective: </strong>This study aimed to assess the prevalence of self-medication practice and identify its associated factors among pregnant women in rural Southwest Shewa, Ethiopia.</p><p><strong>Methods: </strong>A cross-sectional study was conducted on 585 randomly selected pregnant women in selected rural public health institutions from May to July 2021. Data was collected by using an interviewer-administered pretested structured questionnaire. Multivariable logistic regression was used to identify factors associated with self-medication. Variables with <i>p-</i>value <0.05 for the 95% confidence interval of the adjusted odds ratio were considered statistically significant.</p><p><strong>Results: </strong>A total of 585 pregnant women participated in the study with a response rate of 92.3%. The prevalence of self-medication among pregnant women was 19.8%. Primigravidity (AOR = 2.7, 95% CI: 1.2-6.1), lower educational status of husbands (AOR = 3.6, 95% CI: 1.02-12.9), living close to health facilities (AOR = 0.23, 95% CI: 0.09-0.6) and knowing one's own gestational age (AOR = 0.5,95% CI: 0.30-0.9) were significantly associated with self-medication practice.</p><p><strong>Conclusion and recommendation: </strong>One in five of the pregnant women practiced self-medication during the current pregnancy. Primigravidity and lower educational status of husbands were associated with a higher probability of self-medication. Knowing gestational age and living close to health facilities were associated with a lower likelihood of practicing self-medication. Rational drug use has to be promoted among pregnant women. Maternal and child health interventions should also target husbands. Health education has to be strengthened to help pregnant women have a safe pregnancy.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8d/d8/dhps-15-39.PMC9939672.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10771096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and Determinants of Household Medication Storage During the COVID-19 Outbreak in Southwest Ethiopia. 埃塞俄比亚西南部COVID-19疫情期间家庭药物储存的流行情况和决定因素
IF 1.6 Q3 Medicine Pub Date : 2023-01-01 DOI: 10.2147/DHPS.S392564
Semere Welday Kahssay, Workineh Woldeselassie Hammeso, Dawit Getachew, Behailu Dessalegn Woldeselassie

Background: Most households worldwide keep medicines on hand for various reasons, including emergency use, treatment of acute and chronic diseases, and anticipated future use. Being infected or fear of getting COVID-19 in the current pandemic could increase the storage of drugs at home. Thus, this study aimed to assess the prevalence of household storage of medicines and associated factors in southwest Ethiopia during the COVID-19 outbreak.

Methods: A cross-sectional household survey was conducted from February 1 to May 30, 2022. Data on the extent of storage, storage conditions, their current status, disposal methods, among others, were collected through structured interviews and observations. The data were entered into EPI info, exported, and analyzed using Statistical Packages for Social Sciences (SPSS). Bivariate followed by multivariate logistic regression was used to identify associated factors. P-value <0.05 was used as a cut-off point to decide statistical significance.

Results: The magnitude of household medication storage was 48% (95% CI). Analgesics (28.7%) and antibacterial (21.1%) agents were the most predominant class of drugs stored in the households. The most significant proportion of the home-stored medications (34.7%) was reserved for future use, and 31.8% were for treating current medical conditions. The majority of the respondents (84.1%) had never heard/learned about the safe disposal ways of drugs. The presence of children aged less than 5 years in a household [AOR = 1.90 (1.19, 3.05)] and the existence of chronically sick patients in a household [AOR = 4.3 (2.25, 8.45)] were factors significantly associated with household medication storage.

Conclusion: The current study revealed a high prevalence of home medication storage; thus, to lessen or eliminate the negative consequences of storing medications at home, it is necessary to review the medication utilization chain and offer community-based training on proper medication storage and disposal techniques, including establishing take-back programs.

背景:世界上大多数家庭出于各种原因在手边备有药品,包括紧急使用、治疗急慢性疾病以及预期未来使用。在当前的大流行中,被感染或担心感染COVID-19可能会增加家中药物的储存。因此,本研究旨在评估2019冠状病毒病疫情期间埃塞俄比亚西南部家庭储存药品的流行情况及相关因素。方法:于2022年2月1日至5月30日进行横断面入户调查。通过有组织的访谈和观察收集了有关储存范围、储存条件、现状、处置方法等方面的数据。将数据输入EPI信息,导出,并使用社会科学统计软件包(SPSS)进行分析。采用双变量和多变量逻辑回归来确定相关因素。p值结果:家庭药物储存量为48% (95% CI)。镇痛药(28.7%)和抗菌药物(21.1%)是家庭中最主要的药物类别。家庭储存药物中最重要的比例(34.7%)是为将来使用而保留的,31.8%是为了治疗目前的疾病。绝大多数受访者(84.1%)从未听说过/了解过药品的安全处置方式。家庭中存在5岁以下儿童[AOR = 1.90(1.19, 3.05)]和家庭中存在慢性病患者[AOR = 4.3(2.25, 8.45)]是影响家庭药物储存的显著因素。结论:目前的研究表明,家庭药物储存的患病率较高;因此,为了减少或消除在家中储存药物的负面影响,有必要审查药物利用链,并提供以社区为基础的药物储存和处置技术培训,包括建立回收计划。
{"title":"Prevalence and Determinants of Household Medication Storage During the COVID-19 Outbreak in Southwest Ethiopia.","authors":"Semere Welday Kahssay,&nbsp;Workineh Woldeselassie Hammeso,&nbsp;Dawit Getachew,&nbsp;Behailu Dessalegn Woldeselassie","doi":"10.2147/DHPS.S392564","DOIUrl":"https://doi.org/10.2147/DHPS.S392564","url":null,"abstract":"<p><strong>Background: </strong>Most households worldwide keep medicines on hand for various reasons, including emergency use, treatment of acute and chronic diseases, and anticipated future use. Being infected or fear of getting COVID-19 in the current pandemic could increase the storage of drugs at home. Thus, this study aimed to assess the prevalence of household storage of medicines and associated factors in southwest Ethiopia during the COVID-19 outbreak.</p><p><strong>Methods: </strong>A cross-sectional household survey was conducted from February 1 to May 30, 2022. Data on the extent of storage, storage conditions, their current status, disposal methods, among others, were collected through structured interviews and observations. The data were entered into EPI info, exported, and analyzed using Statistical Packages for Social Sciences (SPSS). Bivariate followed by multivariate logistic regression was used to identify associated factors. P-value <0.05 was used as a cut-off point to decide statistical significance.</p><p><strong>Results: </strong>The magnitude of household medication storage was 48% (95% CI). Analgesics (28.7%) and antibacterial (21.1%) agents were the most predominant class of drugs stored in the households. The most significant proportion of the home-stored medications (34.7%) was reserved for future use, and 31.8% were for treating current medical conditions. The majority of the respondents (84.1%) had never heard/learned about the safe disposal ways of drugs. The presence of children aged less than 5 years in a household [AOR = 1.90 (1.19, 3.05)] and the existence of chronically sick patients in a household [AOR = 4.3 (2.25, 8.45)] were factors significantly associated with household medication storage.</p><p><strong>Conclusion: </strong>The current study revealed a high prevalence of home medication storage; thus, to lessen or eliminate the negative consequences of storing medications at home, it is necessary to review the medication utilization chain and offer community-based training on proper medication storage and disposal techniques, including establishing take-back programs.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4b/b7/dhps-15-1.PMC9869910.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10677600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The Utility of Internet-Enabled Antibiotic Self-Medication and Its Associated Factors Among Patients Attending Private Clinics in Kawempe Division in Kampala Capital City, Uganda: Community-Based Cross-Sectional Study. 乌干达首都坎帕拉Kawempe科私人诊所患者使用互联网抗生素自我用药及其相关因素:基于社区的横断面研究。
IF 1.6 Q3 Medicine Pub Date : 2023-01-01 DOI: 10.2147/DHPS.S405072
Joan Nakakande, Ivan Mugisha Taremwa, Miisa Nanyingi, Samuel Mugambe

Introduction: The expanding practice of internet-based antibiotic self-medication raises public health concerns as it increases antibiotic resistance and introduces avoidable risks. This study aims to examine the utility of internet-enabled antibiotic self-medication and its associated factors among patients attending private clinics in Kawempe division in Kampala Capital City, Uganda.

Methods: This was an analytical cross-sectional study that enrolled participants attending private clinics in Kawempe Division's randomly selected zones. These were interviewed using a structured questionnaire, and the data were analyzed using STATA version 12 software. Logistic regression analysis was used, and variables with p ≤ 0.05 were considered as significantly associated with internet-enabled antibiotic self-medication.

Results: Out of the 313 respondents, 246 (79%) reportedly had ever used internet sources to self-medicate with antibiotics. Factors such as being male; single; had knowledge of antibiotics; believed that Internet should be used for antibiotic self-medication; Distance to the nearest medical center/hospital from your residence/workplace of about 5 km and residing near a drug shop/pharmacy that gives antibiotics without a prescription increased internet-enabled antibiotic self-medication. Furthermore, the variables of more than three household members; common practice of antibiotic self-medication in a household; did not agree that one can recover from the illness without a doctor's prescription and medical workers who did not explain adequately the antibiotics medication given for the illness decreased internet-enabled antibiotic self-medication.

Conclusion: This study found that internet-enabled antibiotic self-medication practice is highly utilized and is associated with a variety of individual, household, and healthcare system factors. This necessitates strict adherence to national drug policy regulations governing antibiotic use. Furthermore, community health education is critical in combating such medication practices.

导言:基于互联网的抗生素自我药疗的扩大实践引起了公共卫生关注,因为它增加了抗生素耐药性并引入了可避免的风险。本研究旨在研究互联网抗生素自我用药的效用及其相关因素在乌干达首都坎帕拉卡温佩科私人诊所就诊的患者。方法:这是一项分析性横断面研究,招募了在Kawempe部门随机选择区域的私人诊所就诊的参与者。采用结构化问卷进行访谈,并使用STATA version 12软件对数据进行分析。采用Logistic回归分析,认为p≤0.05的变量与网络抗生素自我用药显著相关。结果:在313名应答者中,据报道有246人(79%)曾使用互联网资源使用抗生素进行自我治疗。比如作为男性;单身;了解抗生素;认为互联网应该用于抗生素自我用药;最近的医疗中心/医院距离您的住所/工作地点约5公里,并且居住在药店/药房附近,无需处方即可提供抗生素,增加了互联网支持的抗生素自我治疗。此外,三个以上家庭成员的变量;家庭中自行使用抗生素药物的普遍做法;不同意没有医生的处方就能从疾病中康复,没有充分解释给这种疾病的抗生素药物的医务工作者减少了互联网上的抗生素自我治疗。结论:本研究发现,互联网支持的抗生素自我用药实践被高度利用,并与各种个人,家庭和医疗保健系统因素相关。这就需要严格遵守有关抗生素使用的国家药物政策法规。此外,社区卫生教育对打击此类用药行为至关重要。
{"title":"The Utility of Internet-Enabled Antibiotic Self-Medication and Its Associated Factors Among Patients Attending Private Clinics in Kawempe Division in Kampala Capital City, Uganda: Community-Based Cross-Sectional Study.","authors":"Joan Nakakande,&nbsp;Ivan Mugisha Taremwa,&nbsp;Miisa Nanyingi,&nbsp;Samuel Mugambe","doi":"10.2147/DHPS.S405072","DOIUrl":"https://doi.org/10.2147/DHPS.S405072","url":null,"abstract":"<p><strong>Introduction: </strong>The expanding practice of internet-based antibiotic self-medication raises public health concerns as it increases antibiotic resistance and introduces avoidable risks. This study aims to examine the utility of internet-enabled antibiotic self-medication and its associated factors among patients attending private clinics in Kawempe division in Kampala Capital City, Uganda.</p><p><strong>Methods: </strong>This was an analytical cross-sectional study that enrolled participants attending private clinics in Kawempe Division's randomly selected zones. These were interviewed using a structured questionnaire, and the data were analyzed using STATA version 12 software. Logistic regression analysis was used, and variables with p ≤ 0.05 were considered as significantly associated with internet-enabled antibiotic self-medication.</p><p><strong>Results: </strong>Out of the 313 respondents, 246 (79%) reportedly had ever used internet sources to self-medicate with antibiotics. Factors such as being male; single; had knowledge of antibiotics; believed that Internet should be used for antibiotic self-medication; Distance to the nearest medical center/hospital from your residence/workplace of about 5 km and residing near a drug shop/pharmacy that gives antibiotics without a prescription increased internet-enabled antibiotic self-medication. Furthermore, the variables of more than three household members; common practice of antibiotic self-medication in a household; did not agree that one can recover from the illness without a doctor's prescription and medical workers who did not explain adequately the antibiotics medication given for the illness decreased internet-enabled antibiotic self-medication.</p><p><strong>Conclusion: </strong>This study found that internet-enabled antibiotic self-medication practice is highly utilized and is associated with a variety of individual, household, and healthcare system factors. This necessitates strict adherence to national drug policy regulations governing antibiotic use. Furthermore, community health education is critical in combating such medication practices.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ca/1f/dhps-15-85.PMC10081524.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9288634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy. 他法非地治疗遗传性甲状腺素转淀粉样蛋白多发性神经病的安全性、有效性和耐受性的最新评价。
IF 1.6 Q3 Medicine Pub Date : 2023-01-01 DOI: 10.2147/DHPS.S338577
Catarina Falcão de Campos, Isabel Conceição

Hereditary amyloid transthyretin (ATTRv) amyloidosis is a devastating hereditary multisystemic disease affecting predominantly the peripheral and autonomic nervous systems and the heart. ATTRv is caused by mutations in the transthyretin (TTR) gene, leading to extracellular deposition of amyloid fibrils in multiple organs including the peripheral nervous system. If untreated, it is associated with a fatal outcome 10-12 years after disease onset. Different treatments are available for patients with ATTRv polyneuropathy. Tafamidis 20 mg is approved in Europe since 2011 for early stages of ATTRv polyneuropathy (stage I - able to walk without support) and it is recommended as first-line therapy in these patients. Tafamidis is a TTR stabilizer that selectively binds to TTR and kinetically stabilizes both wild-type native TTR and mutant TTR. Consequently, it has the potential to prevent the amyloidogenic cascade initiated by TTR tetramer dissociation into its monomers and subsequent misfolding and aggregation. Tafamidis is an oral drug, taken once per day, with proved efficacy, safety and tolerability in ATTRv-PN patients as demonstrated in different clinical trials and open-label extension studies as well in clinical practice setting with around 10 years of experience. Tafamidis treatment started in the earliest stages of the disease is associated with better neurological outcomes. A multidisciplinary approach in referral centres is also fundamental for monitoring patients to assess individual response to treatment.

遗传性淀粉样转甲状腺素淀粉样变性是一种破坏性的遗传性多系统疾病,主要影响外周神经系统和自主神经系统以及心脏。ATTRv是由转甲状腺素(TTR)基因突变引起的,导致包括周围神经系统在内的多个器官的淀粉样蛋白原纤维细胞外沉积。如果不治疗,在发病后10-12年可能导致死亡。对于ATTRv多发性神经病患者,有不同的治疗方法。自2011年以来,他法非底斯20mg在欧洲被批准用于早期ATTRv多发性神经病(I期-能够在没有支持的情况下行走),并被推荐作为这些患者的一线治疗。Tafamidis是一种选择性结合TTR的TTR稳定剂,对野生型原生TTR和突变型TTR都具有动力学稳定性。因此,它有可能阻止由TTR四聚体解离成其单体和随后的错误折叠和聚集引发的淀粉样蛋白级联反应。他法米底斯是一种口服药物,每天服用一次,在不同的临床试验和开放标签扩展研究以及具有大约10年经验的临床实践环境中,证明了ATTRv-PN患者的有效性、安全性和耐受性。在疾病的早期阶段开始他法非地治疗与更好的神经预后相关。转诊中心的多学科方法对于监测患者以评估个人对治疗的反应也是至关重要的。
{"title":"Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy.","authors":"Catarina Falcão de Campos,&nbsp;Isabel Conceição","doi":"10.2147/DHPS.S338577","DOIUrl":"https://doi.org/10.2147/DHPS.S338577","url":null,"abstract":"<p><p>Hereditary amyloid transthyretin (ATTRv) amyloidosis is a devastating hereditary multisystemic disease affecting predominantly the peripheral and autonomic nervous systems and the heart. ATTRv is caused by mutations in the <i>transthyretin</i> (<i>TTR</i>) gene, leading to extracellular deposition of amyloid fibrils in multiple organs including the peripheral nervous system. If untreated, it is associated with a fatal outcome 10-12 years after disease onset. Different treatments are available for patients with ATTRv polyneuropathy. Tafamidis 20 mg is approved in Europe since 2011 for early stages of ATTRv polyneuropathy (stage I - able to walk without support) and it is recommended as first-line therapy in these patients. Tafamidis is a TTR stabilizer that selectively binds to TTR and kinetically stabilizes both wild-type native TTR and mutant TTR. Consequently, it has the potential to prevent the amyloidogenic cascade initiated by TTR tetramer dissociation into its monomers and subsequent misfolding and aggregation. Tafamidis is an oral drug, taken once per day, with proved efficacy, safety and tolerability in ATTRv-PN patients as demonstrated in different clinical trials and open-label extension studies as well in clinical practice setting with around 10 years of experience. Tafamidis treatment started in the earliest stages of the disease is associated with better neurological outcomes. A multidisciplinary approach in referral centres is also fundamental for monitoring patients to assess individual response to treatment.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0a/29/dhps-15-51.PMC9942506.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10762301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Safety Aspects and Rational Use of Testosterone Undecanoate in the Treatment of Testosterone Deficiency: Clinical Insights. 十一酸睾酮治疗睾酮缺乏症的安全性和合理使用:临床观察。
IF 1.6 Q3 Medicine Pub Date : 2023-01-01 DOI: 10.2147/DHPS.S383130
Katherine Campbell, Akhil Muthigi, Armin Ghomeshi, Kyle Schuppe, Max D Sandler, Ranjith Ramasamy

Testosterone deficiency is diagnosed by a serum total testosterone level below 300 ng/dL in combination with symptoms such as decreased energy and libido. These symptoms can be ameliorated by restoring serum testosterone to the physiologic range with testosterone therapy (TT). There are numerous forms of testosterone therapy, such as injectable, transdermal, nasal, and subcutaneous applications. There are also multiple formulations of injection, such as testosterone cypionate, testosterone enanthate, and testosterone undecanoate. Testosterone undecanoate (TU) is a long-acting ester formulation of testosterone that can be provided in an injectable or oral form. Oral testosterone undecanoate is marketed as Andriol, Jatenzo, Tlando, and Kyzatrex. Oral TU provides a convenient option for many patients, which may increase compliance with TT. Injectable testosterone undecanoate is marketed as Aveed and Nebido. Injectable TT remains the most cost-effective therapeutic option and is appropriate for most patients as an initial therapy. This review describes the pharmacokinetics of these testosterone undecanoate products and provides a guide for prescribers using these medications. While many forms of testosterone are appropriate for TT, a patient-centered discussion focused on goals of care should best guide physician prescription of these medications.

睾酮缺乏的诊断是血清总睾酮水平低于300纳克/分升,并伴有能量和性欲下降等症状。这些症状可以通过睾酮治疗(TT)将血清睾酮恢复到生理范围而得到改善。有许多形式的睾酮治疗,如注射,透皮,鼻和皮下应用。注射剂也有多种剂型,如cypionate睾酮、enanthate睾酮和十一酸睾酮。十一酸睾酮(TU)是睾酮的长效酯制剂,可以注射或口服形式提供。口服十一酸睾酮销售为Andriol, Jatenzo, Tlando和Kyzatrex。口服TU为许多患者提供了一个方便的选择,这可能会增加TT的依从性。注射用十一酸睾酮以Aveed和Nebido销售。注射TT仍然是最具成本效益的治疗选择,适合大多数患者作为初始治疗。这篇综述描述了这些十一酸睾酮产品的药代动力学,并为处方者使用这些药物提供了指导。虽然许多形式的睾酮适合于TT,但以患者为中心的讨论应集中在护理目标上,最好指导医生处方这些药物。
{"title":"Safety Aspects and Rational Use of Testosterone Undecanoate in the Treatment of Testosterone Deficiency: Clinical Insights.","authors":"Katherine Campbell,&nbsp;Akhil Muthigi,&nbsp;Armin Ghomeshi,&nbsp;Kyle Schuppe,&nbsp;Max D Sandler,&nbsp;Ranjith Ramasamy","doi":"10.2147/DHPS.S383130","DOIUrl":"https://doi.org/10.2147/DHPS.S383130","url":null,"abstract":"<p><p>Testosterone deficiency is diagnosed by a serum total testosterone level below 300 ng/dL in combination with symptoms such as decreased energy and libido. These symptoms can be ameliorated by restoring serum testosterone to the physiologic range with testosterone therapy (TT). There are numerous forms of testosterone therapy, such as injectable, transdermal, nasal, and subcutaneous applications. There are also multiple formulations of injection, such as testosterone cypionate, testosterone enanthate, and testosterone undecanoate. Testosterone undecanoate (TU) is a long-acting ester formulation of testosterone that can be provided in an injectable or oral form. Oral testosterone undecanoate is marketed as Andriol, Jatenzo, Tlando, and Kyzatrex. Oral TU provides a convenient option for many patients, which may increase compliance with TT. Injectable testosterone undecanoate is marketed as Aveed and Nebido. Injectable TT remains the most cost-effective therapeutic option and is appropriate for most patients as an initial therapy. This review describes the pharmacokinetics of these testosterone undecanoate products and provides a guide for prescribers using these medications. While many forms of testosterone are appropriate for TT, a patient-centered discussion focused on goals of care should best guide physician prescription of these medications.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/49/59/dhps-15-73.PMC10072151.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9264103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Reduction of In-Hospital Preoperative Waiting Time of Elective Surgeries in the Amidst of COVID-19 Pandemic: Experience from Ethiopia. 新冠肺炎疫情下缩短择期手术住院候诊时间:来自埃塞俄比亚的经验
IF 1.6 Q3 Medicine Pub Date : 2022-10-17 eCollection Date: 2022-01-01 DOI: 10.2147/DHPS.S371839
Berhanetsehay Teklewold, Engida Abebe, Dagmawi Anteneh, Etsehiwot Haileselassie

Background: The higher demand for surgical services during the advancement of the COVID-19 pandemic has resulted from the need for a pre-admission negative result, the need for extra resources, and a shortage of skilled expertise. This quality improvement project aimed to reduce the in-hospital preoperative waiting time of elective cases to less than 24 hours.

Methods: The study was conducted in a tertiary care center. Following the collection of baseline data, we formed a multidisciplinary team to analyze the root causes and intervention ideas of delay using fishbone and driver diagrams, respectively. We prioritize key drivers and implemented several low-cost interventions using Plan-Do-Study-Act (PDSA) model. We monitored the average in-hospital preoperative waiting time of patients.

Results: Overall, in-hospital preoperative waiting time for elective cases has been reduced from a baseline of 4.89 days to 1.32 days on average by the end of 10 months of initiating the project. Similarly, monthly elective case cancellation rate due to COVID-19-related reason has been reduced from baseline 62.5% of the total cancellation to 0%. Due to this, the average monthly inpatient bed utilization has increased from 2.21 patients per month during pre-COVID-19 period to 5.9 patients per month in each bed of the surgical ward by the end of the project.

Conclusion: The implementation of a quality improvement project can optimize operation theatre efficiency, inpatient bed utilization, and reduce the surgical backlog. Meticulous and rigorous effort has to be laid down to do root cause analysis, generate feasible change ideas, and continuous follow-up, and testing of multiple PDSA cycles is required to impact an improvement and sustain it in the long run. The emergence of COVID-19 pandemic could be used as an opportunity to reduce the length of stay in the hospital.

背景:COVID-19大流行进展期间对外科服务的更高需求是由于需要入院前阴性结果,需要额外的资源以及缺乏熟练的专业人员。该质量改进项目旨在将择期病例的住院术前等待时间缩短至24小时以内。方法:本研究在三级保健中心进行。在收集基线数据后,我们组成了一个多学科团队,分别使用鱼骨图和驱动图分析延迟的根本原因和干预思路。我们优先考虑了关键驱动因素,并使用计划-执行-研究-行动(PDSA)模型实施了几种低成本干预措施。我们监测了患者的平均住院术前等待时间。结果:总体而言,在项目启动10个月后,择期病例的住院术前等待时间已从基线4.89天减少到平均1.32天。同样,每月因covid -19相关原因取消的选择性病例率也从基线的62.5%降至0%。因此,到项目结束时,平均每月住院床位利用率从covid -19前的每月2.21名患者增加到每月外科病房病床5.9名患者。结论:实施质量改进工程可优化手术室效率,提高住院床位利用率,减少手术积压。细致而严格的工作必须投入到根本原因分析、产生可行的变更想法、持续的跟踪和多个PDSA循环的测试中,以影响改进并在长期内维持它。COVID-19大流行的出现可以作为减少住院时间的机会。
{"title":"Reduction of In-Hospital Preoperative Waiting Time of Elective Surgeries in the Amidst of COVID-19 Pandemic: Experience from Ethiopia.","authors":"Berhanetsehay Teklewold,&nbsp;Engida Abebe,&nbsp;Dagmawi Anteneh,&nbsp;Etsehiwot Haileselassie","doi":"10.2147/DHPS.S371839","DOIUrl":"https://doi.org/10.2147/DHPS.S371839","url":null,"abstract":"<p><strong>Background: </strong>The higher demand for surgical services during the advancement of the COVID-19 pandemic has resulted from the need for a pre-admission negative result, the need for extra resources, and a shortage of skilled expertise. This quality improvement project aimed to reduce the in-hospital preoperative waiting time of elective cases to less than 24 hours.</p><p><strong>Methods: </strong>The study was conducted in a tertiary care center. Following the collection of baseline data, we formed a multidisciplinary team to analyze the root causes and intervention ideas of delay using fishbone and driver diagrams, respectively. We prioritize key drivers and implemented several low-cost interventions using Plan-Do-Study-Act (PDSA) model. We monitored the average in-hospital preoperative waiting time of patients.</p><p><strong>Results: </strong>Overall, in-hospital preoperative waiting time for elective cases has been reduced from a baseline of 4.89 days to 1.32 days on average by the end of 10 months of initiating the project. Similarly, monthly elective case cancellation rate due to COVID-19-related reason has been reduced from baseline 62.5% of the total cancellation to 0%. Due to this, the average monthly inpatient bed utilization has increased from 2.21 patients per month during pre-COVID-19 period to 5.9 patients per month in each bed of the surgical ward by the end of the project.</p><p><strong>Conclusion: </strong>The implementation of a quality improvement project can optimize operation theatre efficiency, inpatient bed utilization, and reduce the surgical backlog. Meticulous and rigorous effort has to be laid down to do root cause analysis, generate feasible change ideas, and continuous follow-up, and testing of multiple PDSA cycles is required to impact an improvement and sustain it in the long run. The emergence of COVID-19 pandemic could be used as an opportunity to reduce the length of stay in the hospital.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/35/dd/dhps-14-185.PMC9585961.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40653473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Drug, Healthcare and Patient Safety
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1